뇌 건강 예측 분석 시장 예측(-2034년) : 솔루션 유형별, 기술, 용도, 최종사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Brain Health Predictive Analytics Market is accounted for $2.4 billion in 2026 and is expected to reach $16.0 billion by 2034 growing at a CAGR of 26.7% during the forecast period. Brain health predictive analytics refers to advanced data-driven methodologies and computational platforms designed to forecast neurological outcomes, identify early biomarkers of cognitive decline, and stratify patient risk for neurodegenerative conditions before clinical symptoms manifest. These systems integrate multi-modal data sources, including electronic health records, neuroimaging, genetic profiles, wearable sensor outputs, and digital cognitive assessments, to build predictive models of brain health trajectories. The technology encompasses machine learning algorithms, statistical modeling frameworks, and clinical decision support tools that enable healthcare providers to implement preventive interventions and optimize resource allocation for populations at elevated risk of dementia, stroke, and other neurological disorders.

Market Dynamics:

Driver:

Aging population burden

The rapidly expanding global aging population is creating unprecedented demand for brain health predictive analytics as the incidence of Alzheimer's disease and related dementias escalates across developed and emerging economies. Healthcare systems face unsustainable costs associated with late-stage neurological care, driving investment in early identification and prevention technologies. Pharmaceutical companies require predictive tools to stratify clinical trial participants and demonstrate treatment efficacy. These demographic and commercial pressures generate sustained market expansion for predictive analytics platforms across hospital, research, and payer environments.

Restraint:

Data integration complexity

The fragmentation of neurological data across disparate electronic health record systems, imaging platforms, and wearable devices creates significant technical barriers for comprehensive brain health predictive analytics deployment. Standardization of neuroimaging protocols, cognitive assessment instruments, and biomarker measurements remains incomplete across healthcare institutions. Privacy regulations governing sensitive brain health data restrict cross-institutional data sharing necessary for robust model training. These interoperability challenges limit the accuracy and generalizability of predictive models outside well-resourced academic medical centers.

Opportunity:

Pharmaceutical partnerships

The pharmaceutical industry's urgent need for predictive biomarkers to support central nervous system drug development presents substantial commercial opportunities for brain health predictive analytics providers. Clinical trial sponsors seek digital endpoints and patient stratification tools to reduce trial failure rates and accelerate regulatory approval timelines. Partnerships between analytics platforms and drug developers create recurring revenue models through licensing agreements and joint development arrangements. These collaborations position predictive analytics as essential infrastructure for the emerging precision neurology therapeutic pipeline.

Threat:

Regulatory uncertainty

The evolving regulatory landscape for artificial intelligence-based diagnostic and predictive tools in healthcare creates compliance risks that threaten market development timelines for brain health predictive analytics. FDA and European Medicines Agency guidance on software-as-medical-device classification remains in flux, creating uncertainty regarding validation requirements and approval pathways. Liability concerns surrounding algorithmic predictions of future cognitive decline complicate commercial deployment. These regulatory ambiguities deter healthcare provider adoption and increase compliance costs for technology developers.

Covid-19 Impact:

The COVID-19 pandemic disrupted routine cognitive assessments and clinical data collection while simultaneously highlighting the value of remote brain health monitoring through predictive analytics platforms. Healthcare providers accelerated digital transformation initiatives that incorporated predictive tools for identifying COVID-related neurological sequelae. Post-pandemic, sustained investment in telehealth infrastructure and remote patient monitoring created favorable conditions for deploying predictive analytics outside traditional clinical settings. The crisis also generated large datasets linking viral infection to cognitive outcomes that improved model training.

The predictive analytics platforms segment is expected to be the largest during the forecast period

The predictive analytics platforms segment is expected to account for the largest market share during the forecast period, due to their comprehensive integration capabilities and established deployment across major healthcare systems. These platforms aggregate multi-source neurological data and deliver actionable risk scores that support clinical decision-making at the point of care. Healthcare payers value predictive analytics for population health management and early intervention cost avoidance. Pharmaceutical companies leverage these platforms for clinical trial optimization and real-world evidence generation. The scalability of cloud-based predictive analytics infrastructure supports enterprise-wide deployment.

The deep learning segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep learning segment is predicted to witness the highest growth rate, driven by its superior capability to identify complex patterns in neuroimaging and multi-modal neurological data that traditional statistical methods cannot detect. Deep neural networks trained on large datasets of brain scans and cognitive assessments achieve diagnostic accuracy levels comparable to specialist neurologists for early-stage dementia detection. These models continuously improve as training data expands across global healthcare networks. The integration of deep learning with federated data architectures enables model development without compromising patient privacy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to advanced healthcare data infrastructure and substantial investment in artificial intelligence research for neurological applications. The United States leads with established electronic health record adoption, major academic research consortia generating large-scale brain health datasets, and favorable regulatory frameworks for software-based medical devices. Major technology companies and healthcare systems collaborate on predictive analytics pilots. Venture capital funding for neurotechnology startups sustains continuous innovation in the predictive analytics space.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding digital health infrastructure and government investment in smart healthcare initiatives across China, Japan, and South Korea. Aging populations in the region create urgent demand for dementia prevention technologies. Government-funded brain research programs generate large national datasets that support predictive model development. The region's technology manufacturing capabilities reduce hardware costs for data collection infrastructure, while growing health insurance coverage expands patient access to predictive screening services.

Key players in the market

Some of the key players in Brain Health Predictive Analytics Market include GE HealthCare, Siemens Healthineers AG, Philips Healthcare, Canon Medical Systems Corporation, FUJIFILM Healthcare, IBM Corporation, Oracle Health, Tempus AI, Verily Life Sciences, IQVIA Holdings Inc., Cambridge Cognition Holdings plc, Cogstate Ltd., Compumedics Limited, Natus Medical Incorporated, EMOTIV Inc., BrainCo Inc. and Neuroelectrics.

Key Developments:

In June 2026, GE HealthCare launched an integrated brain health predictive analytics platform combining MRI imaging data with electronic health records to generate dementia risk scores for primary care physician decision support.

In May 2026, Tempus AI expanded its neurological data analytics portfolio to include predictive models for early Alzheimer's detection based on multi-omic biomarker profiles and longitudinal cognitive assessment trajectories.

In April 2026, IBM Corporation introduced a cloud-based brain health analytics solution leveraging Watson cognitive computing to identify stroke risk patterns from emergency department admission data across hospital networks.

Solution Types Covered:

• Predictive Analytics Platforms
• Brain Health Risk Assessment Software
• Clinical Decision Support Systems
• Digital Biomarker Platforms
• Population Health Analytics
• Remote Brain Monitoring Platforms

Technologies Covered:

• Artificial Intelligence
• Machine Learning
• Deep Learning
• Big Data Analytics
• Cloud Computing
• Digital Biomarkers
• Internet of Medical Things (IoMT)

Applications Covered:

• Alzheimers Disease Prediction
• Dementia Risk Assessment
• Stroke Risk Prediction
• Parkinsons Disease Monitoring
• Cognitive Decline Prediction
• Clinical Trial Optimization
• Population Brain Health Management

End Users Covered:

• Hospitals
• Diagnostic Centers
• Research Institutes
• Pharmaceutical Companies
• Healthcare Payers
• Academic Institutions
• Other End Users

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Brain Health Predictive Analytics Market, By Solution Type

• 5.1 Predictive Analytics Platforms
• 5.2 Brain Health Risk Assessment Software
• 5.3 Clinical Decision Support Systems
• 5.4 Digital Biomarker Platforms
• 5.5 Population Health Analytics
• 5.6 Remote Brain Monitoring Platforms

6 Global Brain Health Predictive Analytics Market, By Technology

• 6.1 Artificial Intelligence
• 6.2 Machine Learning
• 6.3 Deep Learning
• 6.4 Big Data Analytics
• 6.5 Cloud Computing
• 6.6 Digital Biomarkers
• 6.7 Internet of Medical Things (IoMT)

7 Global Brain Health Predictive Analytics Market, By Application

• 7.1 Alzheimer's Disease Prediction
• 7.2 Dementia Risk Assessment
• 7.3 Stroke Risk Prediction
• 7.4 Parkinson's Disease Monitoring
• 7.5 Cognitive Decline Prediction
• 7.6 Clinical Trial Optimization
• 7.7 Population Brain Health Management

8 Global Brain Health Predictive Analytics Market, By End User

• 8.1 Hospitals
• 8.2 Diagnostic Centers
• 8.3 Research Institutes
• 8.4 Pharmaceutical Companies
• 8.5 Healthcare Payers
• 8.6 Academic Institutions
• 8.7 Other End Users

9 Global Brain Health Predictive Analytics Market, By Geography

• 9.1 North America
  • 9.1.1 United States
  • 9.1.2 Canada
  • 9.1.3 Mexico
• 9.2 Europe
  • 9.2.1 United Kingdom
  • 9.2.2 Germany
  • 9.2.3 France
  • 9.2.4 Italy
  • 9.2.5 Spain
  • 9.2.6 Netherlands
  • 9.2.7 Belgium
  • 9.2.8 Sweden
  • 9.2.9 Switzerland
  • 9.2.10 Poland
  • 9.2.11 Rest of Europe
• 9.3 Asia Pacific
  • 9.3.1 China
  • 9.3.2 Japan
  • 9.3.3 India
  • 9.3.4 South Korea
  • 9.3.5 Australia
  • 9.3.6 Indonesia
  • 9.3.7 Thailand
  • 9.3.8 Malaysia
  • 9.3.9 Singapore
  • 9.3.10 Vietnam
  • 9.3.11 Rest of Asia Pacific
• 9.4 South America
  • 9.4.1 Brazil
  • 9.4.2 Argentina
  • 9.4.3 Colombia
  • 9.4.4 Chile
  • 9.4.5 Peru
  • 9.4.6 Rest of South America
• 9.5 Rest of the World (RoW)
  • 9.5.1 Middle East
    • 9.5.1.1 Saudi Arabia
    • 9.5.1.2 United Arab Emirates
    • 9.5.1.3 Qatar
    • 9.5.1.4 Israel
    • 9.5.1.5 Rest of Middle East
  • 9.5.2 Africa
    • 9.5.2.1 South Africa
    • 9.5.2.2 Egypt
    • 9.5.2.3 Morocco
    • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

• 10.1 Industry Value Network and Supply Chain Assessment
• 10.2 White-Space and Opportunity Mapping
• 10.3 Product Evolution and Market Life Cycle Analysis
• 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

• 11.1 Mergers and Acquisitions
• 11.2 Partnerships, Alliances, and Joint Ventures
• 11.3 New Product Launches and Certifications
• 11.4 Capacity Expansion and Investments
• 11.5 Other Strategic Initiatives

12 Company Profiles

• 12.1 GE HealthCare
• 12.2 Siemens Healthineers AG
• 12.3 Philips Healthcare
• 12.4 Canon Medical Systems Corporation
• 12.5 FUJIFILM Healthcare
• 12.6 IBM Corporation
• 12.7 Oracle Health
• 12.8 Tempus AI
• 12.9 Verily Life Sciences
• 12.10 IQVIA Holdings Inc.
• 12.11 Cambridge Cognition Holdings plc
• 12.12 Cogstate Ltd.
• 12.13 Compumedics Limited
• 12.14 Natus Medical Incorporated
• 12.15 EMOTIV Inc.
• 12.16 BrainCo Inc.
• 12.17 Neuroelectrics